Menu
Workout

UC-II®

UC-II® supplies a patented form of undenatured type II collagen for joint health available in a non-fibrous powder. Two published clinical studies show that 40 mg of UC-II once-a-day supports joint comfort, mobility and flexibility.

UC-II® is made from chicken sternum cartilage using a patented, low-temperature, non-enzymatic manufacturing process that ensures the natural levels of undenatured type II collagen as well as its biological activity. UC-II works in the small intestine through a process called oral tolerisation to help slow down the degradation of type II collagen in the joints. Other forms of type II collagen sold as dietary ingredients are denatured or hydrolysed.

Why UC-II® stands out in the joint support market

  • Small and effective 40 mg daily dose
  • Odourless, non-BSE, non-GMO, non-allergenic, non-ETO, and non-irradiated.
  • Can be added to existing formulations, replace ingredients or be launched as a standalone.
  • Clinically studied for joint health in healthy subjects
  • Published peer-reviewed dog and horse joint health research

UC-II® is supported by two published clinical research studies. Randomised, double-blind, placebo-controlled research in healthy subjects shows that 40 mg of UC-II® significantly improved knee extension compared to placebo. UC-II subjects exercised longer before experiencing joint discomfort and recovered faster from joint discomfort after exercising compared to baseline. 

With a consumer friendly formulation, the 40 mg daily dosage of UC-II® allows manufacturers to formulate effective products with a small tablet size. The small dosage also allows manufacturers to add value to multi-ingredient formulations. 

Categories: joint health, dog joint health, equine joint health

Product applications: tablets, capsules, food and beverages

U.S. Patents 5,645,851, 5,637,321, 5,529,786, 5,750,144, 7,083,820, 7,846,487, EPO Patent EP1435906B1 and worldwide patents pending.

Trademark: UC-II®

Cambridge Commodities distributes UC-II® to the following areas:

In this section

Subscribe to receive a copy of the CCL email newsletter